ELEV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ELEV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Elevation Oncology has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.GuruFocus does not calculate Elevation Oncology's interest coverage with the available data. As of today, Elevation Oncology's Altman Z-Score is 0.00.
For the Biotechnology subindustry, Elevation Oncology's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Elevation Oncology's Financial Strength distribution charts can be found below:
* The bar in red indicates where Elevation Oncology's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Elevation Oncology's Interest Expense for the months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the months ended in Mar. 2024 was $-9.87 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $30.81 Mil.
Elevation Oncology's Interest Coverage for the quarter that ended in Mar. 2024 is
GuruFocus does not calculate Elevation Oncology's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Elevation Oncology Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Elevation Oncology's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
Debt to Revenue Ratio | = | Total Debt (Q: Mar. 2024 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0 | + | 30.809) | / | 0 | |
= | N/A |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Elevation Oncology has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elevation Oncology (NAS:ELEV) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Elevation Oncology has the Financial Strength Rank of 7.
Thank you for viewing the detailed overview of Elevation Oncology's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Tammy Furlong | officer: CHIEF FINANCIAL OFFICER | C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
Venbio Global Strategic Gp Iii, L.p. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Venbio Global Strategic Fund Iii, L.p. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Goodman Corey S | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Robert J Adelman | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Aaron Royston | 10 percent owner | 200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063 |
David Dornan | officer: Chief Scientific Officer | C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063 |
Valerie Malyvanh Jansen | officer: Chief Medical Officer | C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Andrew N Schiff | other: Managing Member | PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022 |
Steve Elms | director, other: Managing Member | 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106 |
Venbio Global Strategic Gp Iii, Ltd | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158 |
Qiming U.s. Healthcare Gp Ii, Llc | 10 percent owner | 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004 |
Vertex Global Hc Fund Ii Pte. Ltd. | 10 percent owner | 250 NORTH BRIDGE ROAD, #11-01 RAFFLES CITY TOWER, SINGAPORE U0 179101 |
Walsh Colin | director | C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
From GuruFocus
By GuruFocus Research • 11-02-2023
By PRNewswire PRNewswire • 11-30-2022
By PRNewswire • 09-05-2023
By PRNewswire PRNewswire • 05-15-2023
By PRNewswire PRNewswire • 08-04-2022
By PRNewswire PRNewswire • 07-05-2022
By PRNewswire PRNewswire • 08-03-2022
By PRNewswire PRNewswire • 07-14-2022
By PRNewswire PRNewswire • 01-09-2023
By PRNewswire PRNewswire • 11-03-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.